ArticleJournal of the American College of Surgeons2020
Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.
Article in Journal of the American College of Surgeons, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- The Impact of the COVID-19 Pandemic on Patients with Breast Cancer, Diagnostic Delays and Disease Progression: A Retrospective Study.Iranian journal of medical sciences · 2026Article
- Barriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers.Breast cancer research and treatment · 2025Article
- Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database.Journal of Cancer · 2024Article
- Breast Cancer Screening, Diagnosis, and Surgery during the Pre- and Peri-pandemic: Experience of Patients in a Statewide Health Information Exchange.Annals of surgical oncology · 2023Article
- Impact of the COVID-19 pandemic on new starts to oral oncology medications in the US.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2023Observational
- Factors associated with the time to treat breast cancer in the pandemic period: an observational study.Revista brasileira de enfermagem · 2023Observational
- Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study.Journal of translational medicine · 2022Article
- Evolving operational guidance and experiences for radiology and nuclear medicine facilities in response to and beyond the COVID-19 pandemic.The British journal of radiology · 2022Review
- Factors Associated With Cancer Treatment Delay Among Patients Diagnosed With COVID-19.JAMA network open · 2022Article
- Cancer diagnosis is one quarter lower than the expected cancer incidence in the first year of COVID-19 pandemic in Germany: A retrospective register-based cohort study.Cancer communications (London, England) · 2022Article
- Article
- Has the COVID-19 Pandemic Affected Breast Cancer Stage and Surgical Volume?Frontiers in surgery · 2022Article
- Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19.Annals of surgical oncology · 2021Article
- The Impact of the COVID-19 Pandemic on Cancer Patient's Management-Lithuanian Cancer Center Experience.Healthcare (Basel, Switzerland) · 2021Article
- Surgical Infection Society Guidance for Restoration of Surgical Services during the Coronavirus Disease-2019 Pandemic.Surgical infections · 2021Article
- Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma.Annals of surgical oncology · 2021Article
- Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate controlling for age, sex and cancer type.BMJ health & care informatics · 2021Article
- Impact of COVID-19 on Breast Imaging Practice Operations and Recovery Efforts: A North American Study.Journal of breast imaging · 2021Article
- The Impact of COVID-19 on Breast Surgery Fellowships.Current breast cancer reports · 2021Review
- Lessons Learned: Management of Breast Cancer Patients throughout the COVID-19 Pandemic.Current breast cancer reports · 2021Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to operation and pathologic staging and overall survival (OS). STUDY
designPatients with DCIS or ER+ cT1-2N0 breast cancer treated from 2010 through 2016 were identified in the National Cancer Database. Time to operation was recorded. Factors associated with pathologic upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy.
resultsThere were 378,839 patients identified. Among those undergoing primary surgical procedure, time to operation was within 120 days in > 98% in all groups. Among cT1-2N0 patients selected for NET, operations were performed within 120 days in 59.6% of cT1N0 and 30.9% of cT2N0 patients. Increased time to operation was associated with increased odds of pathologic upstaging in DCIS patients (ER+: 60 to 120 days: odds ratio 1.15; 95% CI, 1.08 to 1.22; more than 120 days: odds ratio 1.44; 95% CI, 1.24 to 1.68; ER-: 60 to 120 days: NS; more than 120 days: odds ratio 1.36; 95% CI, 1.01 to 1.82; 60 days or less: reference), but not in patients with invasive cancer, irrespective of initial treatment strategy. No difference in OS was seen by time to operation in DCIS or NET patients.
conclusionsIncreased time to operation was associated with a small increase in pathologic upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.